Immunovant (IMVT) Assets Average (2019 - 2026)
Immunovant's (IMVT) quarterly Assets Average came in at $1.0 billion in Q1 2026, up 67.85% YoY from $598.6 million in Q1 2025, and up 22.87% on a QoQ basis from $817.7 million in Q4 2025.
Immunovant (IMVT) Assets Average (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Assets Average data on file, last reported at $1.0 billion in Q1 2026.
- Quarterly Assets Average rose 67.85% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 67.85% YoY) and the FY2026 annual result came in at $866.6 million, up 20.15% from the prior year.
- Assets Average climbed to $1.0 billion in Q1 2026, from $817.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $1.0 billion in Q1 2026 to a low of $321.6 million in Q3 2023.
- A 5-year average of $566.8 million and a median of $529.4 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average fell 27.46% — and 2025, when it soared 74.6%.
- Tracing IMVT's Assets Average over 5 years: stood at $442.2 million in 2022, then grew by 13.47% to $501.8 million in 2023, then fell by 6.66% to $468.3 million in 2024, then soared by 74.6% to $817.7 million in 2025, then increased by 22.87% to $1.0 billion in 2026.
- The last three Assets Average figures came in at $1.0 billion (Q1 2026), $817.7 million (Q4 2025), and $622.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 904.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 904.75 Mn |
| Mar 31, 2026 | 1.00 Bn |
| Dec 31, 2025 | 817.68 Mn |
| Sep 30, 2025 | 622.20 Mn |
| Jun 30, 2025 | 718.83 Mn |
| Mar 31, 2025 | 598.58 Mn |
| Dec 31, 2024 | 468.32 Mn |
| Sep 30, 2024 | 552.69 Mn |
| Jun 30, 2024 | 628.02 Mn |
| Mar 31, 2024 | 688.91 Mn |
| Dec 31, 2023 | 501.76 Mn |
| Sep 30, 2023 | 321.65 Mn |
| Jun 30, 2023 | 378.53 Mn |
| Mar 31, 2023 | 431.04 Mn |
| Dec 31, 2022 | 442.19 Mn |
| Sep 30, 2022 | 443.40 Mn |
| Jun 30, 2022 | 487.11 Mn |
| Mar 31, 2022 | 529.37 Mn |
| Dec 31, 2021 | 554.96 Mn |
| Sep 30, 2021 | 477.38 Mn |